BioCatalystWatch
HRMYWorkspace / HRMY / OverviewCompany library
Harmony Biosciences Holdings, Inc. logo

Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. (HRMY)

Website

Price
Market cap
Next catalystAES Annual Meeting, December 2026EPX-100 — ARGUS, Dravet syndrome · Phase 3 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

pitolisant (WAKIX)

Histamine H3 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Pitolisant GR

Upcoming / outlook

  • Timing and evidence

Pitolisant HD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Pitolisant HD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

BP-205

OX2R

PreINDP1P2P3FilingApproved
Upcoming / outlook

BP-205

OX2R

PreINDP1P2P3FilingApproved
Upcoming / outlook

EPX-100 (clemizole hydrochloride)EPX-100 — ARGUS, Dravet syndrome

5-HT2 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

EPX-100 (clemizole hydrochloride)

5-HT2 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

EPX-100 (clemizole hydrochloride)EPX-100 — ARGUS, Dravet syndrome

5-HT2 receptor

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

BP-205

OX2R

PreINDP1P2P3FilingApproved
Upcoming / outlook

Pitolisant GR

Upcoming / outlook

  • Timing and evidence

Pitolisant HD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Pitolisant HD

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

Other pipelines

Pitolisant HD

BP-205

OX2R

BP-205

OX2R

PreINDP1P2P3FilingApproved
BP-205

OX2R

PreINDP1P2P3FilingApproved
BP-205

OX2R

Zygel

Zygel

PreINDP1P2P3FilingApproved
HBS-102

MCHR1

PreINDP1P2P3FilingApproved
TPM-1116

OX2R

PreINDP1P2P3FilingApproved

Approved / commercial

pitolisant (WAKIX)

Histamine H3 receptor

Approved

PreINDP1P2P3FilingApproved

History / paused

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

HRMY PR & News

PR & News

HRMY SEC archive